Stock Worth Watching: What’s Ahead for Avinger Inc After Today’s Huge Decline?

Stock Worth Watching: What's Ahead for Avinger Inc After Today's Huge Decline?

The stock of Avinger Inc (NASDAQ:AVGR) is a huge mover today! About 111,565 shares traded hands. Avinger Inc (NASDAQ:AVGR) has declined 58.26% since April 6, 2016 and is downtrending. It has underperformed by 60.21% the S&P500.
The move comes after 7 months negative chart setup for the $106.57M company. It was reported on Nov, 8 by We have $3.99 PT which if reached, will make NASDAQ:AVGR worth $10.66 million less.

According to Zacks Investment Research, “Avinger, Inc. is engaged in designing, manufacturing and selling image-guided, catheter-based systems to treat peripheral arterial disease. The company’s product consists of Lightbox imaging console, Wildcat, Kittycat, Ocelot, Ocelot PIXL, Ocelot MVRX and Juicebox. Avinger, Inc. is based in Redwood City, California.”

More notable recent Avinger Inc (NASDAQ:AVGR) news were published by: which released: “Avinger Inc. NASDAQ: AVGR” on December 15, 2011, also with their article: “Avinger Inc. (AVGR) Lowers Guidance, Stock Down 40%” published on July 13, 2016, published: “Avinger, Inc. Announces Closing of Public Offering of Common Stock and …” on August 16, 2016. More interesting news about Avinger Inc (NASDAQ:AVGR) were released by: and their article: “Avinger, Inc. Announces Preliminary Second Quarter 2016 Revenue Results” published on July 12, 2016 as well as‘s news article titled: “Avinger, Inc. to Announce Second Quarter 2016 Results on Monday, August 1, 2016” with publication date: July 25, 2016.

AVGR Company Profile

Avinger, Inc., incorporated on March 8, 2007, is a commercial-stage medical device company. The Firm designs, makes and sells image-guided, catheter systems that are used by physicians to treat patients with peripheral arterial disease (PAD). The Firm focuses on introducing products based on its lumivascular platform, which is an intravascular image-guided system. The Firm makes and sells a suite of products in the United States and select European markets. The Company’s products include Lightbox imaging console, as well as its Wildcat, Kittycat and the Ocelot family of catheters, which are designed to allow physicians to penetrate a total blockage in an artery, known as a chronic total occlusion (CTO). The lumivascular platform offers real-time visualization of the inside of the artery during PAD treatment. The lumivascular platform consists of a capital component Lightbox and a range of disposable catheter products, including Ocelot, Ocelot PIXL, Ocelot MVRX and Pantheris.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment